ABSTRACT. Two peaks in the incidence of invasive meningococcal disease (IMD)occur
EPIDEMIOLOGY OF INVASIVE MENINGOCOCCAL DISEASE
The overall case-fatality rate of IMD in children and adults in the United States is 10% to 14%. 2 From 1991 to 2002, the highest incidence of IMD in the United States (9.2 per 100 000) was among infants younger than 1 year (Fig 1) ; the rate among adolescents 11 to 19 years of age (1.2 per 100 000) also was higher than that for the general population. Thirty-eight percent of IMD cases were observed in infants and children younger than 11 years, but adolescents had the highest case-fatality rate (approximately 20%).
Certain patients are at increased risk of IMD, including patients with deficiency of the terminal complement pathway (C5-C9) or C3 and patients with anatomic or functional asplenia (ie, sickle cell disease). Healthy children also can be at increased risk of meningococcal disease if they are traveling to or living in areas outside the United States where IMD is hyperendemic or epidemic or if they are involved in a confirmed outbreak.
In the United States, more than 98% of cases of IMD in children and adults are sporadic, but since 1991, the frequency of localized outbreaks has increased, especially in schools. 6 The proportion of meningococcal disease caused by serogroup Y has increased from 2% in 1989-1991 7 to 37% in 1997-2002. 2 Currently, serogroups B, C, and Y are the major causes of IMD in the United States, each being responsible for approximately one third of all cases. The proportion of cases caused by each serogroup varies by age group; more than half of cases among infants younger than 1 year are caused by serogroup B, for which no vaccine is licensed or available in the United States. 8 Seventy-five percent of all cases of meningococcal disease in people 11 to 18 years of age are caused by serogroups (A, C, Y, or W-135) included in currently available vaccines. 2 The incidence of IMD caused by these vaccine-preventable serotypes peaks in people 18 years of age (1.8 per 100 000), is beginning to increase substantially at 15 years of age, and decreases by 19 years of age (Fig 2) .
Three studies conducted in the United States address the risk of meningococcal disease among college students. [9] [10] [11] Each study demonstrated that the risk of meningococcal disease was higher in college students who reside in dormitories than in other college students. The earliest of these reports described a low overall incidence of meningococcal disease in college students (1 per 100 000 population per year), but IMD occurred 9 to 23 times more frequently in students residing in dormitories than in students residing in other types of accommodations. 11 In the second study, which was a retrospective, cohort investigation conducted in Maryland for the period 1992-1997, the overall incidence of IMD in college students was similar to the incidence in the US population of people the same age (1.74 per 100 000 vs 1.44 per 100 000, respectively), but rates were significantly higher among students living in dormitories compared with students living off campus (3.2 per 100 000 vs 0.96 per 100 000; P = .05). 10 Finally, US surveillance data from the 1998-1999 school year suggested that the overall rate of meningococcal disease among undergraduate college students was lower than the rate among people 18 to 23 years of age who are not enrolled in college (Table 1 ; 0.7 vs 1.5 per 100 000, respectively). Among the approximately 600 000 freshmen who lived in dormitories during this period, the rate (5.1 per 100 000) was higher than any age group in the population other than children younger than 2 years but lower than the threshold of 10 per 100 000 recommended for initiating meningococcal immunization campaigns. 9 Although ample data define the risk for IMD among certain college students, there are no studies among adolescents in living circumstances that may be similar to college dormitories (boarding schools, "sleep away" camps, etc). In the absence of data establishing increased risk, adolescents in these circumstances should be immunized only if they fall into a recommended group by age or underlying medical condition. 
Duration of Protection
In children 2 to 5 years of age, measurable concentrations of antibodies against group A and C polysaccharides decrease substantially during the first 3 years after a single dose of vaccine. 19 Although vaccine-induced protection likely persists in school-aged children and adults for at least 3 years, the efficacy of the group A vaccine administered to children younger than 5 years may decrease markedly within this period of time. In one study, vaccine efficacy in children immunized at younger than 4 years decreased from more than 90% to less than 10%; in children given vaccine at older than 4 years of age, vaccine efficacy was 67% 3 years later.
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Precautions and Contraindications
MPSV4 has been extensively used in mass immunization programs as well as in the military and among international travelers. Adverse reactions to MPSV4 generally are mild; the most frequent reaction is pain and redness at the injection site lasting for 1 or 2 days. Estimates of the incidence of such local reactions have varied, ranging from 4% to 56%. Transient fever occurs in up to 5% of vaccine recipients in some studies but is less common in older children and adults. Most studies report the rate of systemic allergic reactions (eg, urticaria, wheezing, and rash) as 0.0 to 0.1 per 100 000 vaccine doses. 21 Anaphylaxis has been documented in less than 0.1 per 100 000 vaccine doses.
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Meningococcal Conjugate Vaccines
Theoretic Advantage of MCV4
Bacterial polysaccharides, including those comprising the capsule of N meningitidis, are T cell-independent antigens. T cell-independent antigens do not elicit a memory response. They stimulate mature B-lymphocytes but not T-lymphocytes, thus inducing a response that is neither long lasting nor characterized by anamnestic response after subsequent challenge with the same polysaccharide antigen. 23 Kingdom was estimated at 80% in infants, 84% in toddlers, 76% in preschoolers, and 87% in school-aged children. 27 Effectiveness of the meningococcal group C conjugate vaccines within the first year of immunization ranged from 88% to 98% in different age groups. 28 Because the vaccine campaign was initiated in 1999, duration of protection data is not yet available.
However, effectiveness among infants who received 3 doses of vaccine at 2, 3, and 4 months of age decreased by 81% after only 1 year. 28 Although the number of cases remains low, likely in part because of vaccine-induced herd immunity, this study raises important questions about the meningococcal vaccine schedule and the need for a booster dose. Carriage rates of group C meningococci in the United Kingdom decreased by 66% during the campaign; incidence of IMD decreased by 67% in unimmunized children 1 to 17 years of age, demonstrating the ability of the conjugate vaccine to elicit herd immunity. 
Immunologic Correlates of Protection
Studies in military recruits conducted in the United States in the 1960s demonstrated that naturally acquired bactericidal antibodies measured by SBA confer protection from IMD. SBA titers ≥1:4 using human serum as an exogenous complement source (hSBA) are considered the correlate of protection against serogroup C meningococcal disease. 29 This correlate of protection was used in the recent licensure of monovalent serogroup C meningococcal conjugate vaccines in the United Kingdom without the requirement for clinical efficacy trials. 30 However, immunogenicity data supporting the use of these conjugate vaccines were generated by a serum bactericidal assay using baby rabbit serum (rSBA), rather than human serum, as an exogenous complement source.
Further evaluation of rSBA threshold values were performed using vaccine efficacy estimates from postlicensure surveillance in the United Kingdom. Postlicensure surveillance data suggested that an rSBA 4 weeks after immunization of ≥1:8 was most consistent with the observed protective effect. 31 On the basis of these efficacy estimates, rSBA titers of <1:8 were proposed to be predictive of susceptibility to invasive meningococcal disease. The proportion of responders in various clinical trials of meningococcal C conjugate vaccines and on the group C seroprevalence study conducted before introduction of group C conjugate vaccines also provide evidence that rSBA titers of ≥1:8 correlate with short-term protection. 32 There exist little or no similar data linking immune response to efficacy for serogroups A, Y, or W-135.
MCV4 was licensed on the basis of demonstrated noninferiority to MPSV4 for immunogenicity and safety. MPSV4 had been licensed on the basis of efficacy against serogroup A and C meningococcal disease in military recruits. 33 The primary criterion in determining immunogenic noninferiority of MCV4 to MPSV4 was the percentage of adolescents and adults who had an increase in SBA of fourfold or greater after receiving MCV4 compared with the percentage of those after MPSV4 was used. However, for licensure of MCV4, an rSBA of ≥1:128 was considered as "protective," because it would not only predict short-term but also long-term clinical efficacy.
Immunogenicity
A randomized controlled trial compared the immunogenicity of MCV4 and MPSV4 in adolescents 11 to 18 years of age 28 days after immunization. A similar percentage of subjects achieved at least a fourfold increase in rSBA titers in the MCV4 and MPSV groups ( Table 2 ).
The percentage of adolescents with at least a fourfold increase in rSBA was highest for serogroup W-135 (96.7% for MCV4; 95.3% for MPSV4) and lowest for serogroup Y (81.8%
and 80.1%, respectively). The percentage of subjects achieving rSBA geometric mean titer of ≥1:128 was higher than 98% for all meningococcal serogroups in both MCV4 and MPSV4
recipients. 34 
Duration of Protection and Reimmunization
Unlike MPSV4, the duration of protection after MCV4 is not known but is expected to be longer than 3 years; additional studies will be needed to confirm this. To date, the only data concerning reimmunization with MCV4 come from a study in which 76 adolescents previously immunized with MCV4 and 77 adolescents previously immunized with MPSV4 were compared with 88 age-matched vaccine-naive adolescents. 34 SBA was measured in sera from these adolescents before (day 0) and 8 and 28 days after immunization with MCV4 (Table 3) . Adolescents initially immunized with MCV4 had higher rSBA geometric mean titer (GMT) before reimmunization than adolescents initially immunized with MPSV4; this difference reached statistical significance for serogroup A (P <.001) and W-135 (P <.001) but not for serogroups C and Y. In addition, a higher percentage of adolescents initially immunized with MCV4 had protective rSBA titers of 1:128 or above compared with adolescents initially immunized with MPSV4 (Table 3) . Vaccine-naive adolescents had low rSBA before immunization compared with adolescents who had previously received MCV4 or MPSV4.
Response to reimmunization with MCV4 also was assessed by determining the percentage of adolescents initially immunized with MCV4 or MPSV4 with rSBA titers of ≥1:128 before (day 0) and 8 and 28 days after administration of MCV4 and with vaccine-naive controls.
All adolescents in each of the 3 groups achieved rSBA titers of ≥1:128 28 days after MCV4 (Table 3) . Subjects initially primed with MCV4 achieved higher rSBA GMTs compared with vaccine-naive controls for all serogroups except serogroup A. 34 When MCV4 and Td were administered concomitantly, antibody response to diphtheria antigen 28 days after immunization was greater (diphtheria GMT, 120.9 IU/mL) than when Td and MCV4 were administered sequentially 28 days apart (diphtheria GMT, 8.4 IU/mL 28 days after Td dose).
Concomitant Administration of MCV4 and Other Vaccines
Safety
Among adolescents 11 to 18 years of age, safety of administering MCV4 and MPSV4
was assessed in 2 randomized controlled trials. 34 The percentage of subjects reporting systemic adverse events was similar in both groups (Table 4 ). Approximately half of the adolescents experienced at least one systemic adverse reaction, but less than 5% experienced at least one severe systemic reaction. Fever was reported by 3.4% to 5.1% of adolescents who received MCV4 and by 2.5% to 3.0% of adolescents who received MPSV4, a difference that was not significant.
Local adverse reactions were more common among adolescents who received MCV4 than among adolescents who received MPSV4 (Table 5 ). Of adolescents who received MCV4, 13.1% to 16.9% reported pain that limited movement in the arm of injection, compared with 2.6% to 3.9% of adolescents who received MPSV4. These differences in frequency of local reactions could be attributable in part to different methods of administering the 2 vaccines (MCV4 is administered intramuscularly; MPSV4 is administered subcutaneously). The frequency of local adverse reactions reported after MCV4 administration was similar to that reported after Td administration, which, like MCV4, is given intramuscularly.
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Precautions and Contraindications
Immunization with MCV4 is contraindicated among people known to have hypersensitivity to any component of the vaccine, including diphtheria toxoid, and to dry, natural rubber latex, which is used in the vial stopper. Any adverse effect suspected to be associated with MCV4 vaccine should be reported to the Vaccine Adverse Events Reporting System (more information can be obtained by calling 800/822-7967 or by accessing the Web site at www.vaers.org).
Cost of Meningococcal Vaccines
Whether universal immunization of adolescents with tetravalent A, C, Y, W-135 meningococcal vaccine would result in a net cost or a net savings to society is dependent on IMD incidence, which varies by year, the rates of death or permanent sequelae, and the cost of immunization. A recent study from the CDC suggests that universal immunization of adolescents would be cost-effective. 35 However, variations in the epidemiology of and outcomes from IMD 
FUTURE NEEDS
MCV4 has been licensed on the basis of safety and short-term immunogenicity data in adolescents. Several postmarketing studies are planned, including a study to evaluate the duration of antibody responses in participants who received a single dose of MCV4 vaccine or MPSV4 vaccine 5 and 10 years earlier and a study to evaluate safety and immunogenicity when MCV4 is given concomitantly with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap). However, vaccine effectiveness and herd immunity based on the ability of MCV4 to alter transmission patterns cannot be predicted from immunogenicity data alone.
Information on MCV4 effectiveness, duration of protection, and herd immunity effects obtained from MCV4 evaluation studies will be indispensable in guiding prevention policies and formulating recommendations for immunization in other age groups.
MCV4 and other meningococcal conjugate vaccines may be licensed in the United States in the near future for use in other age groups, including children 2 to 10 years of age and infants.
Such vaccines are undergoing clinical trials and are likely to be more immunogenic in infants and young children compared with MPSV4, which currently is the only meningococcal vaccine licensed in the United States for use in young children.
Because meningococcal serogroup B capsular polysaccharide is poorly immunogenic in humans, vaccine development has focused on common surface proteins, including the outer membrane proteins (OMPs) of specific epidemic strains. 36 OMP vaccines have shown good efficacy in older children and adults, but efficacy in infants and young children, in whom rates of disease are highest, has not been demonstrated. In addition, the variability in OMP strains causing endemic disease likely will limit their usefulness in the United States. is critical to prevention of a substantial number of cases of IMD. However, parents and adolescents must understand that MCV4 will not prevent all meningococcal disease, and at least 25% of cases in adolescents are caused by serogroup B. 1 Educating the general public about the benefits of being immunized with MCV4 may foster increased immunization coverage rates for adolescents and substantially decrease the burden of meningococcal disease in the United States.
RATIONALE FOR MENINGOCOCCAL VACCINE RECOMMENDATIONS
MCV4 offers advantages over MPSV4. First, it demonstrates a T-cell dependent characteristic so that children given a second dose have an anamnestic or booster response not found after a second dose of MPSV4. Second, the elevated rSBA 3 years after MCV4 but not after MPSV4 immunization in adolescents suggests a longer duration of immunity than with MPSV4. Third, the experience in the United Kingdom with the monovalent meningococcal serogroup C conjugate vaccine demonstrating a reduction in nasopharyngeal carriage of that serogroup in immunized infants and children as well as herd immunity affecting nonimmunized children suggests that MCV4 also will have similar effects, although data will be necessary to demonstrate these characteristics. Finally, MCV4 should induce antibodies against most strains causing IMD among adolescents 11 years or older.
Because the initial supply of MCV4 will be limited for the next 2 to 3 years, initially only 2 cohorts can be recommended to be immunized routinely. The first, young adolescents at the 11-to 12-year visit, was selected because this is the age when a booster dose of Td already is recommended and when well visits to the pediatrician are more likely to occur than in older adolescents. 2 The AAP also emphasizes the importance of more pediatric patients of this age having well visits for preventive services other than immunization. A recommendation to immunize all 11-to 12-year-olds, therefore, not only is more likely to be feasible compared with older adolescents, but also should be associated with enhancing the importance of the young adolescent visit. The second cohort, entering high school students or 15-year-olds, whichever comes first, was chosen on the basis of 2 factors: the peak IMD incidence and routine medical visits by adolescents 13 years and older. Rates Per 100,000 Population Age (years) Cases Per 100,000 Population
